Persistence on prostaglandin ocular hypotensive therapy: An assessment using medication possession and days covered on therapy

BMC Ophthalmology

Volumn 10, Issue 1, 2010, Pages

  Reardon, Gregory ^a   Schwartz, Gail F ^b   Kotak, Sameer ^c  

^a Informagenics LLC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; BIMATOPROST; CLOPROSTENOL; DRUG DERIVATIVE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F; TRAVOPROST;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG ADMINISTRATION; FACTUAL DATABASE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; AMIDES; CLOPROSTENOL; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC; RETROSPECTIVE STUDIES;

EID: 77949899249     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-10-5     Document Type: Article

References (41)

1. Prevalence of open-angle glaucoma among adults in the United States. DS Friedman RC Wolfs BJ O'Colmain BE Klein HR Taylor S West MC Leske P Mitchell N Congdon J Kempen Eye Diseases Prevalence Research Group, Arch Ophthalmol 2004 122 532 538 10.1001/archopht.122.7.1019 15078671
2. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. I Dielemans JR Vingerling RC Wolfs A Hofman DE Grobbee PT de Jong, Ophthalmology 1994 101 1851 1855 7800368
3. The Barbados Eye Study. Prevalence of open angle glaucoma. MC Leske AM Connell AP Schachat L Hyman, Arch Ophthalmol 1994 112 821 829 8002842
4. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. P Mitchell W Smith K Attebo PR Healey, Ophthalmology 1996 103 1661 1669 8874440
5. The prevalence of glaucoma. B Bengtsson, Br J Ophthalmol 1981 65 46 49 10.1136/bjo.65.1.46 6969603
6. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. FC Hollows PA Graham, Br J Ophthalmol 1966 50 570 586 10.1136/bjo.50.10.570 5954089
7. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. HM Leibowitz DE Krueger LR Maunder RC Milton MM Kini HA Kahn RJ Nickerson J Pool TL Colton JP Ganley JI Loewenstein TR Dawber, Surv Ophthalmol 1980 24 Suppl 335 610 7444756
8. Ocular hypertension. Frequency, course and relation to other disorders occurring in glaucoma, as seen from mass survey of all inhabitants over forty years of age in a Swedish town. U Stromberg, Acta Ophthalmol Suppl 1962 Suppl 69 1 75 13917848
9. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma. GF Schwartz, Am J Ophthalmol 2004 137 1 Suppl 1 S2 10.1016/j.ajo.2003.10.029 14697908
10. Predictors of persistence with antihypertensive therapy: results from the NHANES. LE Bautista, Am J Hypertens 2008 21 183 188 10.1038/ajh.2007.33 18188161
11. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. P Bramlage J Hasford, Cardiovasc Diabetol 2009 8 18 10.1186/1475-2840-8-18 19327149
12. Long-term persistence with antihypertensive drugs in new patients. E Degli Esposti A Sturani M Di Martino P Falasca MV Novi G Baio S Buda M Volpe, J Hum Hypertens 2002 16 439 444 10.1038/sj.jhh.1001418 12037702
13. Adherence and persistence with glaucoma therapy. GF Schwartz HA Quigley, Surv Ophthalmol 2008 53 Suppl 1 57 S68 10.1016/j.survophthal.2008.08.002 19038625
14. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. B Vrijens G Vincze P Kristanto J Urquhart M Burnier, BMJ 2008 336 1114 1117 10.1136/bmj.39553.670231. 25 18480115
15. Treatment for glaucoma: adherence by the elderly. JH Gurwitz RJ Glynn M Monane DE Everitt D Gilden N Smith J Avorn, Am J Public Health 1993 83 711 716 10.2105/AJPH.83.5.711 8484454
16. Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. JH Gurwitz SM Yeomans RJ Glynn BE Lewis R Levin J Avorn, Med Care 1998 36 357 369 10.1097/00005650-199803000-00012 9520960
17. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). DS Friedman HA Quigley L Gelb J Tan J Margolis SN Shah EE Kim T Zimmerman SR Hahn, Invest Ophthalmol Vis Sci 2007 48 5052 5057 10.1167/iovs.07-0290 17962457
18. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. ES Johnson E Mozaffari, Am J Manag Care 2002 8 10 Suppl 249 S254 12188167
19. Rates of discontinuation and change of glaucoma therapy in a managed care setting. JJ Spooner MF Bullano LI Ikeda TR Cockerham WJ Waugh T Johnson E Mozaffari, Am J Manag Care 2002 8 10 Suppl 262 S2670 12188169
20. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. G Reardon GF Schwartz E Mozaffari, Clin Ther 2003 25 1172 1185 10.1016/S0149-2918(03)80074-7 12809964
21. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. GF Schwartz G Reardon E Mozaffari, Am J Ophthalmol 2004 137 1 Suppl 13 S16 10.1016/j.ajo.2003.10.034 14697910
22. Patient persistency with pharmacotherapy in the management of glaucoma. G Reardon GF Schwartz E Mozaffari, Eur J Ophthalmol 2003 13 Suppl 4 44 S52 12948052
23. Persistence and adherence with topical glaucoma therapy. BL Nordstrom DS Friedman E Mozaffari HA Quigley AM Walker, Am J Ophthalmol 2005 140 598 606 16226511
24. A gap analysis approach to assess patient persistence with glaucoma medication. PP Lee JG Walt TH Chiang A Guckian J Keener, Am J Ophthalmol 2007 144 520 524 10.1016/j.ajo.2007.06.023 17692273
25. Discontinuation rates of topical glaucoma medications in a managed care population. FT Shaya CD Mullins W Wong J Cho, Am J Manag Care 2002 8 10 Suppl 271 S277 12188170
26. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Z Zhou R Althin BS Sforzolini R Dhawan, Br J Ophthalmol 2004 88 1391 1394 10.1136/bjo.2003.037713 15489479
27. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. J Wilensky RG Fiscella AM Carlson LS Morris J Walt, Am J Ophthalmol 2006 141 1 Suppl 28 S33 10.1016/j.ajo.2005.09.011 16389058
28. Warning letter. U.S. Food and Drug Administration. 2005 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054796. pdf Accessed February 20, 2010.
29. Health Services Research and the HIPAA Privacy Rule. http:// privacyruleandresearch.nih.gov/pdf/HealthServicesResearchHIPAAPrivacyRule.pdf Accessed April 15, 2009.
30. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. R Platt G Reardon E Mozaffari, Am J Ophthalmol 2004 137 Suppl 1 17 S23 10.1016/j.ajo.2003.10.033 14697911
31. A cost analysis of the prostaglandin analogs. AB Mick S Gonzalez MT Dunbar JJ McSoley, Optometry 2002 73 614 619 12408547
32. Medical therapy cost considerations for glaucoma. RG Fiscella A Green DH Patuszynski J Wilensky, Am J Ophthalmol 2003 136 18 25 10.1016/S0002-9394(03) 00102-8 12834665
33. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. S Deokule S Sadiq S Shah, Ophthalmic Physiol Opt 2004 24 9 15 10.1046/j.1475-1313.2003.00155.x 14687196
34. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. JM Foody AT Joyce AE Rudolph LZ Liu JS Benner, Curr Med Res Opin 2008 24 1987 2000 10.1185/03007990802203279 18554430
35. Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? RH Chapman EM Pelletier PJ Smith CS Roberts, Patient Prefer Adherence 2009 3 265 275 19936170
36. Impact of adherence to statins on chronic heart failure in primary prevention. S Perreault A Dragomir L Blais A Bérard L Lalonde M White, Br J Clin Pharmacol 2008 66 706 716 18754842
37. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. B Vrijens A Belmans K Matthys E de Klerk E Lesaffre, Pharmacoepidemiol Drug Saf 2006 15 115 121 10.1002/pds.1198 16342302
38. Multicenter study of compliance and drop administration in glaucoma. R Kholdebarin RJ Campbell YP Jin YM Buys, Can J Ophthalmol 2008 43 454 461 10.3129/I08-076 18711461
39. An objective evaluation of eyedrop instillation in patients with glaucoma. JL Stone AL Robin GD Novack DW Covert GD Cagle, Arch Ophthalmol 2009 127 732 736 10.1001/archophthalmol.2009.96 19506189
40. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. B Vrijens G Vincze P Kristanto J Urquhart M Burnier, BMJ 2008 336 1114 1117 10.1136/bmj.39553.670231. 25 18480115
41. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. AL Robin GD Novack DW Covert RS Crockett TS Marcic, Am J Ophthalmol 2007 144 533 540 10.1016/j.ajo.2007.06.012 17686450